The competitive moat in metabolic medicine is shifting from raw weight loss to muscle preservation.
To avoid long-term strength loss and metabolic rebounds, drug developers must shift focus from total weight reduction toward maintaining lean muscle mass.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Modern clinical trials are evaluating post-bariatric weight loss quality to ensure body fat is reduced without sacrificial muscle decline.
Clinical developers are shifting focus to combining myostatin inhibitors with incretins to preserve critical lean muscle mass and prevent metabolic rebounds.
Established drugmakers must leverage precise MRI body composition data to defend their efficacy claims against higher-potency competitors.